<DOC>
	<DOCNO>NCT02148393</DOCNO>
	<brief_summary>A randomised control open-label clinical trial compare clinical pregnancy rate fresh embryo transfer elective all-embryo vitrification thaw transfer subsequent cycle high-responders</brief_summary>
	<brief_title>Implantation Enhancement Elective Cryopreservation All Viable Embryos</brief_title>
	<detailed_description>Two-arm randomise , single-centre , control open-label trial . Summarily , woman undergo exogenous gonadotropin ovarian stimulation ART gonadotropin-releasing hormone ( GnRH ) antagonist down-regulated cycle high risk ovarian hyperstimulation syndrome ( OHSS ) include either control ( `` fresh embryo transfer '' ) intervention ( `` subsequent vitrified-warmed embryo transfer '' ) group . Women control group undergo GnRH agonist trigger follow intensified luteal phase support intervention group electively vitrify viable embryo GnRH trigger perform embryo transfer ( ET ) subsequent unstimulated cycle . Ovarian stimulation , ultrasound hormonal monitoring , ovulation induction , oocyte retrieval , embryology procedure , IVF luteal support accord normally perform centre . All woman include undergo artificial ovarian stimulation GnRH antagonist down-regulation daily injection either ganirelix ( Orgalutran® ) cetrorelix ( Cetrotide® ) . Treating physician opt exogenous gonadotropin use accord patient 's profile preference include either recombinant follicle stimulate hormone ( FSH ) highly purified urinary human menopausal gonadotropin ( HP-HMG ) . Ovarian stimulation commence confirm patient pregnant basal level oestradiol , progesterone , FSH luteinising hormone ( LH ) . The stimulation monitor simultaneously pelvic ultrasound hormonal analysis ( oestradiol , progesterone ) , start day 7 stimulation every 1 3 day , accord individual endocrine profile follicular development . Final oocyte maturation trigger 0.2 mg triptorelin ( Decapeptyl® , Gonapeptyl® ) soon 3 follicle ≥17 mm observe . A GnRH agonist prefer trigger agent group reduce risk severe OHSS associate human chorionic gonadotropin ( hCG ) trigger high-responders . Oocyte retrieval perform 36 hour hCG administration either local anaesthesia analgesic premedication general anaesthesia , accord patient preference . IVF/ICSI perform , use specimen sperm make available male progenitor day oocyte retrieval . The choice transfer one two embryo decide clinician consultation mainly depend patient 's age number embryo replace previous treatment cycle , accord Belgian law .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Dimethyl Sulfoxide</mesh_term>
	<criteria>First second IVF/ICSI cycle High response ovarian stimulation ( define presence ≥18 follicle ≥11 mm day GnRH trigger ) GnRH antagonist downregulation Signed informed consent Patients include trial Planned replacement 1 2 blastocyst Other known reason impaired implantation ( i.e . hydrosalpinx , fibroid distort endometrial cavity , Asherman 's syndrome , thrombophilia endometrial tuberculosis ) Oocyte/embryos donation acceptor Embryos plan undergo preimplantation genetic diagnosis/screening Body mass index ≥35 ≤18 Women previously enrol trial Those unable comprehend investigational nature propose study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>